Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effects of HMG-coA Reductase Inhibitor on Rheumatoid Arthritis

This study has been completed.
Information provided by:
Chinese University of Hong Kong Identifier:
First received: November 7, 2007
Last updated: January 26, 2011
Last verified: December 2008

The purpose of this study is:

  1. To evaluate the prevalence of preclinical atherosclerosis in Chinese patients with RA compared to healthy controls.
  2. To determine those clinical and biological measures that best predict the presence of plaque and increased arterial stiffness.
  3. To ascertain the efficacy and safety of rosuvastatin in the prevention of atherosclerosis in patients with RA measured by carotid intima-media thickness (IMT) and pulse wave velocity (PWV).

Condition Intervention Phase
Rheumatoid Arthritis
Drug: Rosuvastatin
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effects of HMG-coA Reductase Inhibitor on Progression of Carotid Intima-Media Thickness and Arterial Stiffness in Rheumatoid Arthritis

Resource links provided by NLM:

Further study details as provided by Chinese University of Hong Kong:

Primary Outcome Measures:
  • Improvement of atherosclerosis by Rosuvastatin therapy, evaluated by IMT and PWV. [ Time Frame: baseline,week24,week52 ]

Secondary Outcome Measures:
  • physical examination,blood pressure,pulse rate,and body weight measurements at each visit.Liver function and CK are performed at baseline,week 12,24 and 52.Correlation between clinical parameters,inflammatory markers and atherosclerosis. [ Time Frame: baseline,week0,week3,week8,week12,week24,week36,week52 ]

Enrollment: 150
Study Start Date: July 2007
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: Rosuvastatin
5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
Other Name: crestor
Placebo Comparator: 2
Drug: Placebo
5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
Other Name: crestor

Detailed Description:

150 consecutive RA patients followed at the Rheumatology clinic of the Prince of Wales Hospital will be recruited for this double-blind, randomized, placebo-control trial. Patients were matched to 150 controls on the basis of age (within 5 years), sex, body mass index (+/-5Kg) and ethnicity for the cross sectional study on the prevalence of subclinical atherosclerosis. Controls were healthy individuals recruited from the same community who underwent similar imaging protocols of the IMT and PWV assessments.

Primary outcome is the improvement of atherosclerosis by Rosuvastatin therapy, evaluated by IMT and PWV.

Secondary outcomes:

  • Prevalence of premature atherosclerosis in RA patients compared to healthy controls in terms of the presence of plague and PWV.
  • Correlation between clinical parameters, inflammatory markers (CRP/hsCRP, TNF-alpha and IL-6) and atherosclerosis (evaluated by IMT, the presence of plaque and PWV).
  • Relation among PWV, ABI and AI in RA patients, and clinical significance of their combination.
  • Determine which segment's PWV has a better relation with RA disease activity.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men or women, 18 years of age or older
  • Clinical diagnosis of RA with a duration of at least 6 month
  • Prednisolone < =10 mg/day
  • Informed consent

Exclusion Criteria:

  • Little or no ability for self-care
  • Type 1 diabetes mellitus
  • Uncontrolled hypertension(> 160/95 mmHg)
  • Total cholesterol > 240 mg/dl, current or recent (within the past 3 months)
  • History of coronary bypass grafting, myocardial infraction within 28days, left ventricular dysfunction (ejection fraction < 40%), significant valvular heart disease
  • Current treatment with ACE inhibitor, angiotensin II receptor blockers or beta-blockers, lipid lowering drug, or contra-indication to statins
  • Current treatment of oral contraceptives, estrogen and progestin was allowed but patient not willing to stop during study
  • Current treatment with antioxidant therapy (Vitamin C or multivitamin)
  • Received intra-articular, intramuscular, or intravenous corticosteroids in the past 4 weeks before screening
  • Clinically significant renal disease(serum creatinine level ≥ 270 µmol/L) or aspartate aminotransferase(AST), alanine aminotransferase ALT), or creatine kinase (CK)≥ 2 X ULN
  • Female of childbearing potential, unwilling to use adequate contraception during the study
  • Current or recent (within the past 3 months) pregnancy and cancer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00555230

School of Pharmacy CUHK
Hong Kong, China
Sponsors and Collaborators
Chinese University of Hong Kong
Principal Investigator: Edmund Kwok Ming Li, MD Chinese University of Hong Kong
  More Information

Responsible Party: Edumun K Li,MD, the Chinese University of Hong Kong Identifier: NCT00555230     History of Changes
Other Study ID Numbers: RA-2007-004
Study First Received: November 7, 2007
Last Updated: January 26, 2011

Keywords provided by Chinese University of Hong Kong:
HMG-CoA reductase inhibitors

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Rosuvastatin Calcium
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Lipid Regulating Agents processed this record on May 25, 2017